Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQLE | Q14534 | 7/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.68 |
| ▸ | ICMT | O60725 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096216 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL17554341 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8625012 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8622512 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940711 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8625008 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL16221426 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940909 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL3096208 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL5603630 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043058-A1 | SHC ENZYMES AND ENZYME VARIANTS | GIVAUDAN SA (CH) | 2026-02-12 | — | — | US | disclosed |
| US-20250361536-A1 | SQUALENE HOPENE CYCLASE (SHC) VARIANTS | GIVAUDAN SA (CH) | 2025-11-27 | — | — | US | disclosed |
| US-12416027-B2 | Squalene hopene cyclase (SHC) variants | GIVAUDAN SA (CH) | 2025-09-16 | — | — | US | disclosed |
| US-20230021613-A1 | SQUALENE HOPENE CYCLASE (SHC) VARIANTS | GIVAUDAN SA (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230021613-A1 | SQUALENE HOPENE CYCLASE (SHC) VARIANTS | GIVAUDAN SA (CH) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043058-A1 | SHC ENZYMES AND ENZYME VARIANTS | SQLE, DHCR7, CYP51A1 | SQLE 1/4885KMT2A 3526/4885MAPT 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.